NCT04541355 - Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions

Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Advanced Head and Neck Squamous Cell CarcinomaLocally Advanced Hypopharyngeal Squamous Cell CarcinomaLocally Advanced Laryngeal Squamous Cell CarcinomaLocally Advanced Oral Cavity Squamous Cell CarcinomaLocally Advanced Oropharyngeal Squamous Cell CarcinomaPathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IV Hypopharyngeal Carcinoma AJCC v8Stage IV Laryngeal Cancer AJCC v8Stage IV Lip and Oral Cavity Cancer AJCC v8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IVA Hypopharyngeal Carcinoma AJCC v8Stage IVA Laryngeal Cancer AJCC v8Stage IVA Lip and Oral Cavity Cancer AJCC v8Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IVB Hypopharyngeal Carcinoma AJCC v8Stage IVB Laryngeal Cancer AJCC v8Stage IVB Lip and Oral Cavity Cancer AJCC v8Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IVC Hypopharyngeal Carcinoma AJCC v8Stage IVC Laryngeal Cancer AJCC v8Stage IVC Lip and Oral Cavity Cancer AJCC v8Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Interventions

DRUG

Cisplatin

Given IV

OTHER

Hearing Handicap Inventory for Adults - Screening

Patient self-assessment questionnaire to measure probability of hearing impairment

RADIATION

Radiation Therapy

Radiation therapy will be delivered according to the standard of care

DRUG

Sodium Thiosulfate

Given IV

Trial Locations (1)

94143

University of California, San Francisco, San Francisco